16-Dehydropregnenolone acetate

16-Dehydropregnenolone acetate (16-DPA), a sterols compound, is an orally active 17α-hydroxylase and 5α-reductase inhibitor. 16-Dehydropregnenolone is also a potent bile acid receptor (BAR) /farnesoid X receptor (FXR) antagonist. 16-Dehydropregnenolone hypolipidemic and anticancer effects. 16-Dehydropregnenolone acetate (16-DPA) is the drug intermediate that can be used for synthesis of Dexamethasone (HY-14648) and related other steroidal pharmacophores[1][2][3].

Product Specifications

CAS Number

[979-02-2]

Product Name Alternative

16-DPA

UNSPSC

12352211

Hazard Statement

H302-H315-H319-H335

Target

5 alpha Reductase; Cytochrome P450; Drug Intermediate; FXR

Related Pathways

Metabolic Enzyme/Protease; Others

Applications

Cancer-programmed cell death

Field of Research

Cancer; Cardiovascular Disease

Smiles

CC(C1=CC[C@@]2([H])[C@]3([H])CC=C4C[C@@H](OC(C)=O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)=O

Molecular Formula

C23H32O3

Molecular Weight

356.50

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P362+P364-P405-P501

References & Citations

[1]Kumar M, et al., Aza-annulation on the 16-dehydropregnenolone, via tandem intermolecular aldol process and intramolecular Michael addition. Bioorg Med Chem Lett. 2011 Apr 15;21 (8) :2232-7.|[2]Ramakrishna R, Kumar D, Bhateria M, Gaikwad AN, Bhatta RS. 16-Dehydropregnenolone lowers serum cholesterol by up-regulation of CYP7A1 in hyperlipidemic male hamsters. J Steroid Biochem Mol Biol. 2017 Apr;168:110-117. |[3]Deng Z, Wang X, Wang F, Qin Z, Cui Y, Sun Y, Sun L. Pharmacokinetics and tissue distribution study of 16-dehydropregnenolone liposome in female mice after intravenous administration. Drug Deliv. 2016 Oct;23 (8) :2787-2795.